Despite the initial emphasis on MTHFD2 as a gene induced in cancers, all the way back to the Mejia and MacKenzie 1985 article, the targeting of this enzyme could hold as much or even greater potential as an immunomodulatory strategy. The gene discussed is MTHFD2; the disease is cancer.